Willow Biosciences (TSX: WLLW) (OTCQX: CANSF), a leading developer of biosynthetic production systems for high-value, plant-derived active pharmaceutical ingredients (“APIs”) and intermediates, has completed a series of studies evaluating the safety and anti-inflammatory, anti-aging, and antimicrobial properties of its cannabigerol (“CBG”) when used on skin. The studies were conducted in collaboration with Signum Biosciences Inc., Willow’s development partner. The company announced that the studies show that Willow CBG is safe and effective when used on the skin and around the eye area; data indicates the ingredient can act as a more potent antioxidant and anti-inflammatory for certain skin applications than plant-derived cannabidiol (“CBD”). Willow will present the results of its findings at the upcoming Society for Investigative Dermatology (“SID”) meeting, scheduled for May 3–8, 2021; the company also noted it will make the full data available on its website on May 3. “Demonstrating the safety and benefit of a new ingredient like Willow’s CBG is a critical step in commercialization and it’s one that we take seriously at the Company,” said Willow Biosciences chief operating officer Dr. Chris Savile in the press release. “Willow’s CBG is now clinically tested to be safe for sensitive skin and demonstrated in the laboratory to act as a potent antioxidant, anti-inflammatory and anti-microbial. Most interestingly, Willow CBG was shown to be as potent or more potent than CBD, in some cases up to twice as potent, in the performed assays. We believe the clinical work on human skin and in vitro models with CBG are the first of their kind to be reported and we are very excited to share the results with our stakeholders and industry.”
To view the full press release, visit https://cnw.fm/XNy9R
About Willow Biosciences Inc.
Willow is a Canadian biotechnology company based in Vancouver, British Columbia, which produces high-purity, plant-derived compounds that provide building blocks for the global pharmaceutical, health and wellness, and consumer packaged goods industries. Willow’s current focus is on the production of cannabinoids for the treatment for pain, anxiety, obesity and brain disorders, among other significant indications. Willow’s science team has a proven track record of developing manufacturing technologies for high-purity compounds in pain and cancer treatments. Willow’s manufacturing process creates a consistent, scalable and sustainable product that allows for the discovery and development of new life-changing drugs. For more information about the company, visit www.WillowBio.com.
NOTE TO INVESTORS: The latest news and updates relating to WLLW are available in the company’s newsroom at http://cnw.fm/WLLW
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CBDWire.com
Do you have questions or are you interested in working with CNW? Ask Our Editor
CBDWire is part of the InvestorBrandNetwork.